Published in Am J Respir Crit Care Med on October 08, 2010
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis | NCT02632123
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis (Rehab-IPF) | NCT03222648
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 3.42
MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med (2013) 2.31
A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol (2015) 2.21
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 2.17
Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2013) 2.16
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. PLoS One (2013) 1.51
Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med (2012) 1.46
Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung (2013) 1.45
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One (2013) 1.20
Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One (2012) 1.14
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res (2013) 1.10
PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest (2014) 1.06
FAK-related nonkinase is a multifunctional negative regulator of pulmonary fibrosis. Am J Pathol (2013) 1.04
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med (2014) 1.02
Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir Res (2012) 0.99
Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis. J Pharmacol Exp Ther (2014) 0.99
Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol (2013) 0.98
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Measuring extracellular pH in a lung fibrosis model with acidoCEST MRI. Mol Imaging Biol (2015) 0.98
Quantitative computed tomography imaging of interstitial lung diseases. J Thorac Imaging (2013) 0.97
Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther (2015) 0.95
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther (2014) 0.94
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema. BMJ Open (2012) 0.90
The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med (2015) 0.90
The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest (2012) 0.89
Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest (2014) 0.88
The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial. Respir Res (2014) 0.87
The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes (2014) 0.87
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med (2012) 0.87
Blocking TGFβ via Inhibition of the αvβ6 Integrin: A Possible Therapy for Systemic Sclerosis Interstitial Lung Disease. Int J Rheumatol (2011) 0.87
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline. Chest (2016) 0.86
Protein tyrosine phosphatase α mediates profibrotic signaling in lung fibroblasts through TGF-β responsiveness. Am J Pathol (2014) 0.85
Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis. Respir Res (2014) 0.84
High-resolution CT scoring system-based grading scale predicts the clinical outcomes in patients with idiopathic pulmonary fibrosis. Respir Res (2014) 0.84
Personalized medicine: applying 'omics' to lung fibrosis. Biomark Med (2012) 0.84
Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev (2016) 0.84
Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS One (2016) 0.84
The value of CT for disease detection and prognosis determination in combined pulmonary fibrosis and emphysema (CPFE). PLoS One (2014) 0.84
Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.84
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int (2015) 0.83
IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Adv Ther (2015) 0.83
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med (2015) 0.83
Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Des Devel Ther (2013) 0.83
Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings. F1000Prime Rep (2014) 0.83
A novel profibrotic mechanism mediated by TGFβ-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. J Pathol (2015) 0.83
IPF clinical trial design and endpoints. Curr Opin Pulm Med (2014) 0.83
Sphingolipid regulation of tissue fibrosis. Open Rheumatol J (2012) 0.82
Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS One (2013) 0.82
The future of the development of medicines in idiopathic pulmonary fibrosis. BMC Med (2015) 0.82
mRNAs and miRNAs in whole blood associated with lung hyperplasia, fibrosis, and bronchiolo-alveolar adenoma and adenocarcinoma after multi-walled carbon nanotube inhalation exposure in mice. J Appl Toxicol (2015) 0.82
Cytokines in chronic respiratory diseases. F1000 Biol Rep (2013) 0.81
Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis (2015) 0.81
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med (2014) 0.81
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med (2015) 0.81
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis (2015) 0.80
A cohort study of mortality predictors in patients with acute exacerbation of chronic fibrosing interstitial pneumonia. BMJ Open (2013) 0.80
Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice. Lab Invest (2014) 0.80
Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med (2014) 0.80
Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med (2015) 0.80
Idiopathic pulmonary fibrosis: time to get personal? Am J Respir Crit Care Med (2013) 0.79
Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulm Med (2015) 0.79
Inadequate Palliative Care in Chronic Lung Disease. An Issue of Health Care Inequality. Ann Am Thorac Soc (2016) 0.78
The Role of Cardiopulmonary Exercise Test in IPF Prognosis. Pulm Med (2013) 0.78
Interstitial lung diseases in the hospitalized patient. BMC Med (2015) 0.78
Recent advances in understanding idiopathic pulmonary fibrosis. F1000Res (2016) 0.78
Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency. PLoS One (2013) 0.78
Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. Biomed Res Int (2015) 0.78
Idiopathic pulmonary fibrosis: new insights on functional characteristics at diagnosis. Can Respir J (2014) 0.78
MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. J Hum Genet (2016) 0.78
Clinical Course and Changes in High-Resolution Computed Tomography Findings in Patients with Idiopathic Pulmonary Fibrosis without Honeycombing. PLoS One (2016) 0.78
Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clin Med Insights Circ Respir Pulm Med (2016) 0.77
Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.77
Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis. PLoS One (2013) 0.77
Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res (2015) 0.77
Secreted frizzled related proteins inhibit fibrosis in vitro but appear redundant in vivo. Fibrogenesis Tissue Repair (2014) 0.77
Long-term outcome and use of 6-minute walk test in West Highland White Terriers with idiopathic pulmonary fibrosis. J Vet Intern Med (2014) 0.77
Altered Hypoxic-Adenosine Axis and Metabolism in Group III Pulmonary Hypertension. Am J Respir Cell Mol Biol (2016) 0.77
State of the art in the diagnosis and management of interstitial lung disease. Clujul Med (2015) 0.76
Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. J Biol Chem (2015) 0.76
Candidate genes of idiopathic pulmonary fibrosis: current evidence and research. Appl Clin Genet (2016) 0.76
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. BMJ Open Respir Res (2015) 0.76
Aortic carboxypeptidase-like protein (ACLP) enhances lung myofibroblast differentiation through transforming growth factor β receptor-dependent and -independent pathways. J Biol Chem (2013) 0.76
Challenges in accurate quantitation of lysophosphatidic acids in human biofluids. J Lipid Res (2014) 0.76
Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis (2016) 0.76
The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. Acad Radiol (2016) 0.76
Implantation of fibrin gel on mouse lung to study lung-specific angiogenesis. J Vis Exp (2014) 0.76
Intratracheal instillation of high dose adenoviral vectors is sufficient to induce lung injury and fibrosis in mice. PLoS One (2014) 0.76
BARD1 mediates TGF-β signaling in pulmonary fibrosis. Respir Res (2015) 0.76
Cthrc1 lowers pulmonary collagen associated with bleomycin-induced fibrosis and protects lung function. Physiol Rep (2017) 0.75
The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One (2017) 0.75
Mouse Lung Fibroblast Resistance to Fas-Mediated Apoptosis Is Dependent on the Baculoviral Inhibitor of Apoptosis Protein 4 and the Cellular FLICE-Inhibitory Protein. Front Physiol (2017) 0.75
iTRAQ-Based Proteomics Reveals Novel Biomarkers for Idiopathic Pulmonary Fibrosis. PLoS One (2017) 0.75
Calpain 1 regulates TGF-β1-induced epithelial-mesenchymal transition in human lung epithelial cells via PI3K/Akt signaling pathway. Am J Transl Res (2017) 0.75
Densitometric and local histogram based analysis of computed tomography images in patients with idiopathic pulmonary fibrosis. Respir Res (2017) 0.75
A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis. ERJ Open Res (2017) 0.75
Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis (2016) 0.75
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS One (2017) 0.75
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med (2005) 4.03
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. Am J Med (2005) 2.67
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.32
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest (2003) 2.16
Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2010) 2.03
Clinical problem-solving. Anchors away. N Engl J Med (2007) 2.02
Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.00
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med (2005) 1.90
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2014) 1.80
Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med (2012) 1.79
Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med (2002) 1.76
Clinical problem-solving. Why "why" matters. N Engl J Med (2004) 1.72
Nosocomial pneumonia: state of the science. Am J Infect Control (2006) 1.65
Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest (2008) 1.64
Idiopathic interstitial pneumonias: CT features. Radiology (2005) 1.61
A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm (2007) 1.61
Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology (2013) 1.57
Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest (2009) 1.56
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med (2014) 1.54
Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J (2013) 1.54
Respiratory bronchiolitis-interstitial lung disease: long-term outcome. Chest (2007) 1.53
Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 1.52
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med (2013) 1.51
Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol (2013) 1.51
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax (2009) 1.46
Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc (2006) 1.44
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc (2014) 1.42
Clinical problem-solving. A perfect storm. N Engl J Med (2005) 1.41
Clinical problem-solving. Diagnosis still in question. N Engl J Med (2002) 1.38
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med (2007) 1.37
Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med (2002) 1.37
Racial disparities in clinical trials. N Engl J Med (2002) 1.35
Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med (2010) 1.30
Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest (2007) 1.28
Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest (2013) 1.26
Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis. Chest (2004) 1.24
The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med (2004) 1.22
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax (2012) 1.21
Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest (2009) 1.17
The case for diversity in academic internal medicine. Am J Med (2004) 1.16
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung (2010) 1.11
Achieving diversity in academic internal medicine: recommendations for leaders. Am J Med (2006) 1.10
Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med (2011) 1.02
Silicone injection causing acute pneumonitis: a case series. Lung (2009) 0.99
Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Respir Med (2007) 0.98
Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax (2007) 0.97
Workshop on idiopathic pulmonary fibrosis in older adults. Chest (2010) 0.96
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology (2014) 0.96
The age of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 0.95
Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology (2011) 0.95
Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology (2013) 0.95
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med (2012) 0.94